Blood test could predict treatment effectiveness months earlier in breast cancer
pharmafile | March 6, 2018 | News story | Manufacturing and Production, Research and Development | Cancer, ICR, Institute of Cancer Research, Royal Marsden NHS Foundation Trust, breast cancer, palbociclib, pharma
A team of scientists at The Institute of Cancer Research in London and The Royal Marsden NHS Foundation Trust have developed a blood test which could analyse whether a breast cancer patient is responding to the treatment palbociclib in two to three weeks, potentially reaching a judgement months earlier than current testing allows.
The test provides huge benefits over the current system, whereby women with breast cancer must undergo a scan and wait two to three months before it is confirmed that palbociclib is proving to be an effective intervention. It works by identifying tumour DNA which was entered the bloodstream; researchers then compare the amount of the gene PIK3CA detected before treatment and 15 days after beginning treatment.
In trials of the test investigating 73 women with the PIK3CA mutation, 52 of whom received palbociclib, it was found that patients who had a small decrease in PIK3CA circulating DNA at 15 days had a median progression-free survival of just 4.1 months. However, patients with a large decrease in PIK3CA demonstrated a median progression-free survival of 11.2 months.
The findings mean that, for the patients with low progression-free survival, treatment has not been effective and this can be identified much earlier, allowing for treatment to be altered.
While the test has proved effective so far, the team stressed that more testing is necessary to replicate the findings before it can be applied in a clinical setting.
“Palbociclib is one of a new class of drugs that delays cancer progression for patients with advanced breast cancer, but it’s not effective for everybody. The problem is we have to wait for two to three months before doing a scan to see if the therapy is working,” explained Professor Nicholas Turner, Professor of Molecular Oncology at the ICR and Consultant Medical Oncologist at The Royal Marsden. “Our new study found that a blood test for cancer DNA in the first two weeks of treatment indicated whether the drug was likely to be effective. Having an early indication of how likely a treatment is to work might allow us to adapt treatment – switching some patients to an alternative drug that is more likely to benefit them.”
Matt Fellows
Related Content
Novartis receives SMC approval for early breast cancer treatment
Novartis has announced that its treatment for early breast cancer, Kisqali (ribociclib), has received approval …
Micrima announces upcoming launch of new UK breast cancer assessment
Breast cancer remains one of the leading health threats to women over 35 in the …
Pierre Fabre partners with Know Your Lemons Foundation for breast cancer awareness
The campaign focuses on early detection and education Pierre Fabre Laboratories has announced a partnership …
